Epidemiology, Management, and Outcome of Invasive Fungal Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation in China: A Multicenter Prospective Observational Study

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 6, 2015, Pages 1117-1126

  Sun, Yuqian ^a   Meng, Fanyi ^b   Han, Mingzhe ^c   Zhang, Xi ^d   Yu, Li ^e   Huang, He ^f   Wu, Depei ^g   Ren, Hanyun ^h   Wang, Chun ⁱ   Shen, Zhixiang ^j   Ji, Yu ^a   Huang, Xiaojun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b FIRST MILITARY MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

^e CHINESE PLA GENERAL HOSPITAL   (China)

^f ZHEJIANG UNIVERSITY   (China)

^g THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^h PEKING UNIVERSITY FIRST HOSPITAL   (China)

ⁱ SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^j SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

more..

Author keywords

Allogeneic; Autologous; China; Fungal infection; Stem cells; Transplant

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; MICAFUNGIN; THYMOCYTE ANTIBODY; TRIAZOLE DERIVATIVE; VORICONAZOLE; MYELOABLATIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD; BONE MARROW; CHILD; CHINA; CHRONIC GRAFT VERSUS HOST DISEASE; DIABETES MELLITUS; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFANT; INTESTINAL MUCOSITIS; INVASIVE FUNGAL DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYCOSIS; NEUTROPENIA; NEUTROPHIL COUNT; OBSERVATIONAL STUDY; ORAL MUCOSITIS; OVERALL SURVIVAL; PATIENT CARE; PROGNOSIS; PROPHYLAXIS; PROSPECTIVE STUDY; RISK FACTOR; UMBILICAL CORD BLOOD; ADVERSE EFFECTS; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CHRONIC DISEASE; CLINICAL TRIAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; MICROBIOLOGY; MYCOSES; PATHOLOGY; SIBLING; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; UNRELATED DONORS;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; CHINA; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MYCOSES; MYELOABLATIVE AGONISTS; NEUTROPENIA; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SIBLINGS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TRIAZOLES; UNRELATED DONORS;

EID: 84941266297     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.03.018     Document Type: Article

References (28)

1. Bhatti Z., Shaukat A., Almyroudis N.G., Segal B.H. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia 2006, 162:1-15.
2. Kontoyiannis D.P., Marr K.A., Park B.J., et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010, 50:1091-1100.
3. Neofytos D., Horn D., Anaissie E., et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009, 48:265-273.
4. Pagano L., Caira M., Nosari A., et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007, 45:1161-1170.
5. Upton A., Kirby K.A., Carpenter P., et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007, 44:531-540.
6. Arendrup M.C., Dzajic E., Jensen R.H., et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 2013, 19:E343-E353.
7. Mousset S., Buchheidt D., Heinz W., et al. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2014, 93:13-32.
8. Alothman A.F., Al-Musawi T., Al-Abdely H.M., et al. Clinical practice guidelines for the management of invasive Candida infections in adults in the Middle East region: expert panel recommendations. J Infect Public Health 2014, 7:6-19.
9. Ullmann A.J., Akova M., Herbrecht R., et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 2012, 18(Suppl 7):53-67.
10. Sun Y., Huang H., Chen J., et al. Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China. Tumor Biol 2015, 36:757-767.
11. The diagnostic criteria and treatment guideline of invasive fungal infection in patients with Hematological disease/malignances (3rd version). Zhonghua Nei Ke Za Zhi [Chinese Journal of Internal Medicine] 2010, 49:451-454. The Chinese Invasive Fungal Infection Committee, [Article in Chinese].
12. De Pauw B., Walsh T.J., Donnelly J.P., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
13. Golan Y. Overview of transplant mycology. Am J Health Syst Pharm 2005, 62(8 Suppl 1):S17-S21.
14. O'Brien S.N., Blijlevens N.M., Mahfouz T.H., Anaissie E.J. Infections in patients with hematological cancer: recent developments. Hematology Am Soc Hematol Educ Program 2003, 1:438-472.
15. Kurosawa M., Yonezumi M., Hashino S., et al. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol 2012, 96:748-757.
16. Hoenigl M., Zollner-Schwetz I., Sill H., et al. Epidemiology of invasive fungal infections and rationale for antifungal therapy in patients with haematological malignancies. Mycoses 2011, 54:454-459.
17. Li L., Wang J., Zhang W., et al. Risk factors for invasive mold infections following allogeneic hematopoietic stem cell transplantation: a single center study of 190 recipients. Scand J Infect Dis 2012, 44:100-107.
18. Post M.J., Lass-Floerl C., Gastl G., Nachbaur D. Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients. Transpl Infect Dis 2007, 9:189-195.
19. Mikulska M., Raiola A.M., Bruno B., et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant 2009, 44:361-370.
20. Labbé A.C., Su S.H., Laverdière M., et al. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. Biol Blood Marrow Transplant 2007, 13:1192-1200.
21. National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections. National Comprehensive Cancer Network (NCCN) guidelines. Available at: . Accessed 2 October 2014. http://www.nccn.org.
22. Wang J., Zhan P., Zhou R., et al. Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials. Med Oncol 2010, 27:1082-1088.
23. Shen Y., Huang X.J., Wang J.X., et al. Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study. Int J Clin Pharmacol Ther 2013, 51:738-745.
24. The diagnostic criteria and treatment guideline of invasive fungal infection in patients with Hematological disease/malignances (4th version). Zhonghua Nei Ke Za Zhi [Chinese Journal of Internal Medicine] 2013, 52:704-709. The Chinese Invasive Fungal Infection Committee, [Article in Chinese].
25. Freifeld A.G., Bow E.J., Sepkowitz K.A., et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011, 52:e56-e93.
26. Mendes E.T., Dulley F., Basso M., et al. Healthcare-associated infection in hematopoietic stem cell transplantation patients: risk factors and impact on outcome. Int J Infect Dis 2012, 16:e424-e428.
27. Guo F., Yang Y., Kang Y., et al. Invasive candidiasis in intensive care units in China: a multicenter prospective observational study. J Antimicrob Chemother 2013, 68:1660-1668.
28. Girmenia C., Finolezzi E., Federico V., et al. Invasive Candida infections in patients with haematological malignancies and hematopoietic stem cell transplant recipients: current epidemiology and therapeutic options. Mediterr J Hematol Infect Dis 2011, 3:e2011013.